Viewing
Opinion|Videos|November 18, 2026

Extending Treatment Intervals in wAMD

Second-generation anti-VEGF agents have expanded achievable dosing intervals in neovascular AMD, yet clinicians must weigh durability claims against monocular status, hemorrhage at presentation, and the realities of patient follow-up.

In "Extending Treatment Intervals in wAMD," our panel explores how far treatment intervals can be pushed without compromising disease control. Durability claims for newer anti-vascular endothelial growth factor (anti-VEGF) agents have shifted how far retina specialists are willing to extend patients with wet age-related macular degeneration (wAMD), but comfort levels still vary. Dr. Javaheri describes growing confidence in extending patients, noting that he is no longer anxious when a patient returns late after a hospitalization, because these agents appear to provide a sturdier margin of disease control. He finds this especially valuable for older patients who resist frequent visits, and he often uses trial outcomes to explain why reaching a three- or four-month interval is a realistic goal.

Dr. Kitchens describes a practical recalibration: where 12 weeks once marked the outer limit, 16 weeks has become his new standard. He holds monocular patients and those who presented with hemorrhage at that ceiling, while extending a small number of stable patients with healthy fellow eyes to five months. Dr. Kim is most comfortable at 16 weeks and is cautious about longer intervals for practical reasons. Missed appointments, travel, and caregiver availability create unplanned extensions, and she believes patients are more reliable about visits when they know an injection is expected, making roughly three treatments a year a sustainable sweet spot.

On whether treatment can ever stop, Dr. Kim may move patients caught very early to an as-needed approach but returns to treat-and-extend if fluid recurs. Dr. Dhoot is similarly reluctant to stop, particularly in monocular eyes or after hemorrhage, though he occasionally allows a monitored treatment holiday. The panel concludes that extensions should be individualized rather than driven by labeled maximums alone.

Our next episode, "Navigating Payer Requirements in wAMD," turns to how coverage rules, step therapy, and copay assistance determine what patients actually receive.


Related to this article